top_banner
Cancer News

Recent Breast Cancer News
More women with early-stage breast cancer may be able to avoid chemotherapy (October 10, 2018)

Results from a large clinical trial called TAILORx showed that more women with early-stage breast cancer may now be able to avoid chemotherapy after surgery. The women who participated in the study had... Continue Reading

What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer? (July 25, 2018)

Currently it is recommended that most postmenopausal women with hormone receptor–positive early stage breast cancer be treated with 5 additional years of aromatase inhibitor (AI) therapy following completion... Continue Reading

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer (July 23, 2018)

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor... Continue Reading

Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients (July 9, 2018)

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to... Continue Reading

U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation (June 21, 2018)

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA... Continue Reading

Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer (April 19, 2018)

CancerConnect News: According to an Italian research team the three aromatase inhibitors approved for the treatment of postmenopausal hormone receptor–positive early stage breast cancer have no significant... Continue Reading

FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer (March 26, 2018)

CancerConnect News: On December 20, 2017, the Food and Drug Administration granted regular approval to Perjeta (pertuzumab) for use in combination with Herceptin (trastuzumab) and chemotherapy as adjuvant... Continue Reading

At-home Genetic Testing may be Convenient, but it isn’t Complete (March 20, 2018)

March 14, 2018 https://www.statnews.com/2018/03/14/genetic-testing-23andme-brca/   Home delivery for everything from fresh produce to custom-selected clothing has become a way of life for many Americans.... Continue Reading

FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer (March 12, 2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment... Continue Reading

Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer (February 21, 2018)

A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer (TNBC), according... Continue Reading

Next Page »